Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra

被引：0
|
作者：
Mueller, U. A. [1 ]
机构：
[1] Univ Klinikum Jena, Innere Med Klin 3, FB Endokrinol & Stoffwechselerkrankungen, D-07740 Jena, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2011年 / 136卷 / 11期
关键词：
DPP-4; inhibitor; glucagon-like peptide-1; sulfonylureas; oral antidiabetic drugs; ischemic preconditioning;
D O I：
10.1055/s-0031-1272566
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：547 / 547
页数：1
相关论文
共 50 条
  • [1] Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro
    Nauck, M. A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (11) : 546 - 546
  • [2] Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?
    Ahren, Bo
    CURRENT DIABETES REPORTS, 2011, 11 (02) : 83 - 90
  • [3] Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
    Sutton, Jon M.
    Clark, David E.
    Dunsdon, Stephen J.
    Fenton, Garry
    Fillmore, Amanda
    Harris, Neil V.
    Higgs, Chris
    Hurley, Chris A.
    Krintel, Sussie L.
    MacKenzie, Robert E.
    Duttaroy, Alokesh
    Gangl, Eric
    Maniara, Wiesia
    Sedrani, Richard
    Namoto, Kenji
    Ostermann, Nils
    Gerhartz, Bernd
    Sirockin, Finton
    Trappe, Joerg
    Hassiepen, Ulrich
    Baeschlin, Daniel K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (03) : 1464 - 1468
  • [4] Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?
    Bo Ahrén
    Current Diabetes Reports, 2011, 11 : 83 - 90
  • [5] Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
    Hollander, Priscilla A.
    Kushner, Pamela
    POSTGRADUATE MEDICINE, 2010, 122 (03) : 71 - 80
  • [6] An update on DPP-4 inhibitors in the management of type 2 diabetes
    Cahn, Avivit
    Cernea, Simona
    Raz, Itamar
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (04) : 409 - 419
  • [7] Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
    Gallwitz, Baptist
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 1 - 9
  • [8] DPP-4 inhibitors and their potential role in the management of type 2 diabetes
    Barnett, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (11) : 1454 - 1470
  • [9] Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
    Kishimoto, Miyako
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 187 - 195
  • [10] The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
    Choe, Eun Yeong
    Cho, Yongin
    Choi, Younjeong
    Yun, Yujung
    Wang, Hye Jin
    Kwon, Obin
    Lee, Byung-Wan
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    DIABETES & METABOLISM JOURNAL, 2014, 38 (03) : 211 - 219
12345